Prof. Min Xiao 肖敏
Chief Physician, Professor
Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Minimally invasive Mammotome surgery for benign and malignant breast tumors. Endoscopic immediate and delayed breast reconstruction (Stage I and II). Modified radical mastectomy, breast-conserving oncoplastic surgery, and sentinel lymph node biopsy including internal mammary nodes.
Dr. Xiao holds an MD and serves as Professor, Chief Physician, and Deputy Director of Ward 3, Department of Breast Surgery. A senior visiting scholar at MD Anderson Cancer Center, Dr. Xiao has led two National Natural Science Foundation projects and five provincial-level projects. Research funding exceeds 1.3 million RMB. Dr. Xiao has published 10 SCI papers as first or corresponding author.
Professional roles
- Youth Member, Breast Cancer Professional Committee, China Anti-Cancer Association
- Member and Standing Committee Member of the Youth Committee, Breast Disease Professional Committee, Heilongjiang Medical Doctor Association
- Standing Committee Member and Secretary-General, Breast Disease Professional Committee, Heilongjiang Branch of Chinese Association of Integrative Medicine
- Member, Breast Cancer Professional Committee, Beijing Cancer Prevention and Treatment Society
Name order: in Chinese the family name comes first (Xiao Min). Papers usually list the name as Min Xiao or Xiao M.
Selected publications
20 papers on PubMed matched by name and affiliation; 14 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Immunol, 2026 (senior author): Establishment and evaluation of novel prognostic biomarkers based on systemic coagulation-inflammation index and related genes in breast cancer. PubMed 42558555
- Int J Surg, 2026 (first author): Adebrelimab in combination with dalpiciclib and endocrine therapy as neoadjuvant treatment for HR+/HER2- early breast cancer: an exploratory study. PubMed 41729711
- Transl Oncol, 2025 (senior author): Triglyceride-glucose index and triglyceride-glucose-body mass index as prognostic factors for early stage breast cancer patients receiving neoadjuvant chemotherapy. PubMed 39884219
- Adv Healthc Mater, 2025 (first author): Ru-Ph Nanozyme-Based Hydrogels for Tumor Chemodynamic Therapy by Enhancing Enzyme Catalytic Efficiency Through Multiple Pathways. PubMed 39716831
- Gland Surg, 2024 (senior author): Comparison of clinical characteristics and pathologic complete response rate after neoadjuvant chemotherapy in women under 35 years and older women with breast cancer. PubMed 39678411
- J Chemother, 2024 (senior author): Recent advances in caspase-3, breast cancer, and traditional Chinese medicine: a review. PubMed 37936479
- Front Oncol, 2024 (senior author): Association of immune inflammatory biomarkers with pathological complete response and clinical prognosis in young breast cancer patients undergoing neoadjuvant chemotherapy. PubMed 38380360
- Diagn Pathol, 2024 (senior author): Estrogen receptor-negative/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapy. PubMed 38178166
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion